AVDL VS VKTX Stock Comparison

Performance

AVDL
100/100

AVDL returned 58.04% in the last 12 months. Based on SPY's performance of -21.06%, its performance is above average giving it a score of 100 of 100.

VKTX
100/100

VKTX returned 121.58% in the last 12 months. Based on SPY's performance of -21.29%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

AVDL
80/100

5 analysts offer 12-month price targets for AVDL. Together, they have an average target of 10.67, the most optimistic target put AVDL at 12 within 12-months and the most pessimistic has AVDL at 9.

VKTX
75/100

3 analysts offer 12-month price targets for VKTX. Together, they have an average target of 18.67, the most optimistic target put VKTX at 21 within 12-months and the most pessimistic has VKTX at 15.

Sentiment

AVDL
70/100

AVDL had a bullish sentiment score of 70.23% across Twitter and StockTwits over the last 12 months. It had an average of 6.78 posts, 3.03 comments, and 4.97 likes per day.

VKTX
70/100

VKTX had a bullish sentiment score of 69.61% across Twitter and StockTwits over the last 12 months. It had an average of 61.73 posts, 47.71 comments, and 199.28 likes per day.

Technicals

AVDL
11/100

AVDL receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

VKTX
11/100

VKTX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

AVDL
10/100

AVDL has missed earnings 7 times in the last 20 quarters.

VKTX
10/100

VKTX has missed earnings 9 times in the last 20 quarters.

Profit

AVDL
10/100

Out of the last 20 quarters, AVDL has had 1 profitable quarters and has increased their profits year over year on 1 of them.

VKTX
10/100

Out of the last 20 quarters, VKTX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

AVDL
56/100

AVDL has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

VKTX
53/100

VKTX has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Avadel Pharmaceuticals plc Ordinary Share Summary

Nasdaq / AVDL

Healthcare

Drug Manufacturers - Specialty & Generic

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Viking Therapeutics, Inc Summary

Nasdaq / VKTX

Healthcare

Biotechnology

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Power up your portfolio